The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.
dc.contributor.author | Howell, Anthony | |
dc.contributor.author | Mackintosh, J | |
dc.contributor.author | Jones, Mary | |
dc.contributor.author | Redford, J | |
dc.contributor.author | Wagstaff, John | |
dc.contributor.author | Sellwood, R A | |
dc.date.accessioned | 2010-11-22T17:09:44Z | |
dc.date.available | 2010-11-22T17:09:44Z | |
dc.date.issued | 1988-10 | |
dc.identifier.citation | The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. 1988, 24 (10):1567-72 Eur J Cancer Clin Oncol | en |
dc.identifier.issn | 0277-5379 | |
dc.identifier.pmid | 3208800 | |
dc.identifier.doi | 10.1016/0277-5379(88)90046-6 | |
dc.identifier.uri | http://hdl.handle.net/10541/116013 | |
dc.description.abstract | In the criteria used for assessment of response to treatment for advanced breast cancer the definition of no change (NC) is clear; however, there is no indication of the duration of stabilization required for patients to qualify for this category of response. We have made the assumption that NC is a worthwhile category of response if the overall time to progression (TTP) and survival of this group is not significantly different from patients with partial remissions (PR). Two hundred and sixty-three evaluable patients treated with endocrine therapy and 302 evaluable chemotherapy-treated patients were studied and the TTP and survival curves for PR and periods of NC from 1 to 6 months compared. For the endocrine-treated patients the TTP and survival curves for NC became non-significantly different from the PR curves after 4 and 5 months respectively. For chemotherapy-treated patients the TTP curves became non-significantly different from PR at 4 months and for survival the period was 3 months. In order to define NC as a useful category of response and to eliminate the possibility that NC taken for a shorter period could simply represent a slowly progressive tumour, we suggest that the minimum period of disease stabilization be taken as 5 months for both endocrine- and chemotherapy-treated patients. | |
dc.language.iso | en | en |
dc.subject | Anticancerous Combined Chemotherapy Protocols | en |
dc.subject | Breast Cancer | en |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Ovariectomy | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Tamoxifen | |
dc.subject.mesh | Time Factors | |
dc.title | The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. | en |
dc.type | Article | en |
dc.contributor.department | CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K. | en |
dc.identifier.journal | European Journal of Cancer & Clinical Oncology | en |
html.description.abstract | In the criteria used for assessment of response to treatment for advanced breast cancer the definition of no change (NC) is clear; however, there is no indication of the duration of stabilization required for patients to qualify for this category of response. We have made the assumption that NC is a worthwhile category of response if the overall time to progression (TTP) and survival of this group is not significantly different from patients with partial remissions (PR). Two hundred and sixty-three evaluable patients treated with endocrine therapy and 302 evaluable chemotherapy-treated patients were studied and the TTP and survival curves for PR and periods of NC from 1 to 6 months compared. For the endocrine-treated patients the TTP and survival curves for NC became non-significantly different from the PR curves after 4 and 5 months respectively. For chemotherapy-treated patients the TTP curves became non-significantly different from PR at 4 months and for survival the period was 3 months. In order to define NC as a useful category of response and to eliminate the possibility that NC taken for a shorter period could simply represent a slowly progressive tumour, we suggest that the minimum period of disease stabilization be taken as 5 months for both endocrine- and chemotherapy-treated patients. |